<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04068090</url>
  </required_header>
  <id_info>
    <org_study_id>TIPN in China</org_study_id>
    <nct_id>NCT04068090</nct_id>
  </id_info>
  <brief_title>Taxane Induced Peripheral Neuropathy in Chinese Patients With Breast Cancer</brief_title>
  <official_title>Taxane Induced Peripheral Neuropathy in Chinese Patients With Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect clinical data, blood samples, and self reported
      symptoms of peripheral neuropathy from Chinese patients with breast cancer after treatment
      with taxanes. This data will be used to develop predictive markers for neuropathy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 23, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Total score from the FACT-GOG-Ntx questionnaire</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Total score from the FACT-GOG-Ntx questionnaire for peripheral neuropathy, ranging from 0-44,higher value represents a worse outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Predictive value of genetic variants for the development of neuropathy</measure>
    <time_frame>In the two weeks before start treatment</time_frame>
    <description>SNPs related to peripheral neuropathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total score from the EORTC QLQ - CIPN20 questionnaire</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Total score from the EORTC QLQ - CIPN20 questionnaire for peripheral neuropathy, ranging from 20-80,higher value represents a worse outcome</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Patients with CIPN</arm_group_label>
    <description>Patients with peripheral neuropathy after treatment with taxanes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without CIPN</arm_group_label>
    <description>Patients treated with taxanes and don't develop will be enrolled to this cohort and matched to a specified subject with neurotoxicity based on age, tumor stage, chemotherapy regimen or total taxane dosage</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patient Questionnaires</intervention_name>
    <description>FACT-Ntx, EORTC-CIPN20</description>
    <arm_group_label>Patients with CIPN</arm_group_label>
    <arm_group_label>Patients without CIPN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood Collection</intervention_name>
    <description>biomarker analysis</description>
    <arm_group_label>Patients with CIPN</arm_group_label>
    <arm_group_label>Patients without CIPN</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, DNA,Peripheral Blood Mononuclear Cells (PBMC)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Chinese breast cancer patients treated with taxanes
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of breast cancer

          -  Females aged 16 and older

          -  Planning to receive or previous treated with taxanes

        Exclusion Criteria:

          -  Poorly controlled or insulin-dependent diabetes or other condition likely to
             predispose to neurotoxicity
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hongnan Mo, MD</last_name>
    <phone>+86-10-87788200</phone>
    <email>mhnzlyynk@outlook.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongnan Mo, MD</last_name>
      <phone>8610-87788103</phone>
      <email>mhnzlyynk@outlook.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 15, 2019</study_first_submitted>
  <study_first_submitted_qc>August 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Ma Feiï¼ŒMD</investigator_full_name>
    <investigator_title>Deputy Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

